glioma
Foundation Medicine Assay Nabs FDA Approval as CDx for Ojemda in Pediatric Patients
The FoundationOne test can be used to identify patients with relapsed or refractory BRAF-altered pediatric low-grade glioma who may be eligible for therapeutic options.
Scientists in California and Michigan said that their FastGlioma algorithm can improve detection of tumor infiltration at the margins of surgery sites.
FDA Approves Thermo Fisher Oncomine Dx Target Test as CDx for Servier's Voranigo Brain Cancer Drug
The approval expands the clinical indications for the test, which was previously approved as a CDx for non-small cell lung cancer, thyroid cancer, and bile duct cancer drugs.
Datar Cancer Genetics Aims to Bring Circulating Glial Cell Assay to US to Aid Brain Cancer Diagnosis
Premium
The India-based firm expects to obtain regulatory clearance and launch its TriNetra-Glio test from its facility in North Carolina in the next two years.
NIH Launches New Childhood Cancer Genomics Program
Pediatric and young adult patients treated at facilities affiliated with the NCI-sponsored Children's Oncology Group gain new, broad access to tumor molecular profiling.